Email this article 
REMOTE RESULTS OF SUBLINGUAL ALLERGENSPECIFICIMMUNOTHERAPY AT POLLINOSIS PATIENTS - FIVE YEARS'RESEARCH
- Authors: Manzhos M.V.1, Fedenko ES1, Myagkova MA1, Keropyan GA1, Shkadov SA1, Peretrukhin AI1, Manzhos MV2, Fedenko ES3, Myagkova MA4, Keropyan GA3, Shkadov SA2, Peretruhin AI2
-
Affiliations:
- City clinical hospital № 4
- Institute of immunology
- Institute physiologically active substances of the Russian Academy of Science
- Issue: Vol 8, No 3 (2011)
- Pages: 31-36
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/788
- DOI: https://doi.org/10.36691/RJA788
- ID: 788
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
immunotherapy (SLiT) at pollinosis patients.
Methods. 25 patients at the age from 19 till 50 years old with an allergic rhinitis and asthma (35%) sensitized to
artemisia were under the supervision. SLiT was administered in the period since September 2003 till May 2006
with pollen allergen («Sevapharma», Czech Republik). The average total dose of the allergen per one patient
at the end of the third year was 189999 PNU. Clinical efficiency was estimated annually and in 30 months after
discontinuation of SLiT. Frequency and intensity of symptoms during the pollen season, requirement for medicines,
FEV1 parameters and results of prick tests were considered.
Results. good and excellent results after three courses of immunotherapy demonstrated 23 patients (92%), satisfactory
- 2 patients (8%). The results were remained at 22 patients (88%) within the next 30 months. at 3 patients
(12%) increase of rhinoconjunctivitis symptoms was noted, and 3 (12%) showed expansion of a sensibilisation
spectrum. Further increase of intensity and frequency of asthma symptoms, decrease in indicators FEV1 was not
registered.
Conclusion. SLiT is a highly effective method of treatment for patients with seasonal rhinitis and leads to the
clinical results remaining more than 2 years at the majority of patients.
About the authors
Marina Valentinovna Manzhos
Email: mmv_kinel@mail.ru
E S Fedenko
M A Myagkova
G A Keropyan
S A Shkadov
A I Peretrukhin
M V Manzhos
City clinical hospital № 4City clinical hospital № 4
E S Fedenko
Institute of immunologyInstitute of immunology
M A Myagkova
Institute physiologically active substances of the Russian Academy of ScienceInstitute physiologically active substances of the Russian Academy of Science
G A Keropyan
Institute of immunologyInstitute of immunology
S A Shkadov
City clinical hospital № 4City clinical hospital № 4
A I Peretruhin
City clinical hospital № 4City clinical hospital № 4
References
- Passalacqua G., Lombardi C., Troise C., Canonica G.W. Sublingual immunotherapy: certainties, unmet needs and future directions. Eur. Ann. Allergy Clin. Immunol. 2009, v. 41 (6), p. 163-170.
- WHO Position Paper on Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53 (44), p. 1-42.
- Jacobsen L., Niggemann B., Dreborg S. et al. Specific immunotherapy has long-term preventive effect on seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007, v. 62, p. 943-948.
- Marogna M., Tomassetti D., Bernasconi A. et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 2008, v. 101 (2), p. 206-211.
- Mungan D., Misirligil Z., Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite sensitive patients with rhinitis and asthma: a placebo controlled study. Ann. Allergy Asthma Immunol. 1999, v. 82, p. 485-490.
- Reider N. Sublingual immunotherapy for allergic rhinoconjunctivitis - the seeming and the real. Int. Arch. Allergy Immunolog. 2005, v. 137 (3), p. 181-186.
- Marogna M., Spadolini I., Massolo A. et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004, v. 59, p. 1205-1210.
- Madonini E., Agostinis F. et al. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int. J. Immunopathol. Pharmacol. 2003, v. 16 (1), p. 73-79.
- Rienzo V.D., Marcucci F., Puccinelli P. et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy. 2003, v. 33 (2), p. 206-210.
- Marogna M., Bruno M., Massolo A., Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: A long-term (13-year) retrospective study in real life. Int. Arch. Allergy Immunol. 2007, v. 142 (1), p. 70-78.
- Vourdas D., Syrigou E., Potamianou P. et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy. 1998, v. 53, p. 662-672.
- La Rosa M., Ranno C., Andra C. et al. Double-blind placebo controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 1999, v. 104, p. 425-432.
- Novembre E., Galli E., Landi F. et al. Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2004, v. 114, p. 851-857.
- Smith H., White P., Annila I. et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2004, v. 114 (4), p. 831-837.
- Wilson D.R., Lima M.I., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and metaanalysis. Allergy. 2005, v. 60 (l), p. 4-12.
Supplementary files
